Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.

Pitocco, D., Tartaglione, L., Viti, L., Di Leo, M., Pontecorvi, A., Caputo, S., SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?, <<DIABETES RESEARCH AND CLINICAL PRACTICE>>, 2020; 2020 (N/A): 1-3. [doi:10.1016/j.diabres.2020.108162] [https://hdl.handle.net/10807/221587]

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Pitocco, D;Tartaglione, L;Viti, L;Di Leo, M;Pontecorvi, A;Caputo, S
2020

Abstract

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.
Inglese
Pitocco, D., Tartaglione, L., Viti, L., Di Leo, M., Pontecorvi, A., Caputo, S., SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?, <<DIABETES RESEARCH AND CLINICAL PRACTICE>>, 2020; 2020 (N/A): 1-3. [doi:10.1016/j.diabres.2020.108162] [https://hdl.handle.net/10807/221587]
File in questo prodotto:
File Dimensione Formato  
SARS-COV2 DPP4.pdf

accesso aperto

Licenza: Non specificato
Dimensione 405.53 kB
Formato Adobe PDF
405.53 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/221587
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact